Conexeu Sciences Inc. Common Stock (CNXU) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN US20715F1003

Price
2.83 USD
Market cap
79.82 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-53.36 %
Return on assets (ROA)
-51.03 %

Conexeu Sciences Inc. Common Stock financials

Fiscal year20242025
Revenue0.00 USD0.00 USD
Operating income-643,042.00 USD-3.96 m USD
EBIT-455,362.00 USD-3.92 m USD
Net income-471,867.00 USD-3.92 m USD
Diluted EPS – continuing operations-0.02 USD-0.19 USD

Full history since 2024, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Conexeu Sciences Inc. Common Stock

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.